DDInter1628 DDInter462
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) NUDT18
NUDT18 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) KLHL9
KLHL9 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) TSEN2
TSEN2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Ruxolitinib {u} (Compound) upregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Haemorrhage intracranial
Haemorrhage intracranial {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) NUDT18
NUDT18 {u} (Gene) is regulated by {v} (Gene) RAB4A
RAB4A {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ruxolitinib {u} (Compound) downregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is regulated by {v} (Gene) SIK1
SIK1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Ruxolitinib (Compound) downregulates NUDT18 (Gene) and NUDT18 (Gene) is upregulated by Dabrafenib (Compound)
Ruxolitinib (Compound) upregulates KLHL9 (Gene) and KLHL9 (Gene) is upregulated by Dabrafenib (Compound)
Ruxolitinib (Compound) downregulates TSEN2 (Gene) and TSEN2 (Gene) is downregulated by Dabrafenib (Compound)
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Dabrafenib (Compound)
Ruxolitinib (Compound) upregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is downregulated by Dabrafenib (Compound)
Ruxolitinib (Compound) causes Haemorrhage intracranial (Side Effect) and Haemorrhage intracranial (Side Effect) is caused by Dabrafenib (Compound)
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Ruxolitinib (Compound) downregulates NUDT18 (Gene) and NUDT18 (Gene) is regulated by RAB4A (Gene) and RAB4A (Gene) is upregulated by Dabrafenib (Compound)
Ruxolitinib (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is regulated by SIK1 (Gene) and SIK1 (Gene) is bound by Dabrafenib (Compound)